IPCA Labs Q1FY27 consolidated net profit rises 72% to ₹4,019 crore
IPCA Laboratories posted a 72% YoY rise in Q1FY27 consolidated net profit to ₹4,019 crore, driven by a 21% revenue increase to ₹27,881 crore. Export income led the charge with a 34% surge, while EBITDA margins expanded significantly to 22.88%. Standalone net profit also grew 42% to ₹3,733 crore.
*this image is generated using AI for illustrative purposes only.
IPCA Laboratories reported a significant improvement in profitability for the first quarter of FY27, with consolidated net profit rising to ₹4,019 crore compared to ₹2,332 crore in the corresponding period last year. The company’s revenue also strengthened, reaching ₹27,881 crore versus ₹23,089 crore year-on-year, reflecting robust top-line growth alongside operational efficiency gains.
The firm’s operating performance showed marked acceleration, with EBITDA (before forex gain/loss and other income) jumping to ₹6,379 crore from ₹4,246 crore in the prior year. This represents a substantial expansion in operating leverage, as the EBITDA margin widened to 22.88% from 18.39% in the previous quarter.
Financial Highlights
| Metric: | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Revenue: | ₹27,881 crore | ₹23,089 crore | +21% |
| EBITDA (before forex/other income): | ₹6,379 crore | ₹4,246 crore | +50% |
| EBITDA Margin: | 22.88% | 18.39% | +449 bps |
| Net Profit (Consolidated): | ₹4,019 crore | ₹2,332 crore | +72% |
Segment Performance
Export-led growth was the primary driver for the quarter. Export income surged 34% to ₹9,354 crore, while domestic formulations income grew 13% to ₹10,821 crore. Within exports, institutional sales saw the sharpest rise, growing 107% to ₹1,198 crore, followed by generics at 27% growth to ₹3,400 crore.
Standalone results also reflected strong momentum, with standalone net profit rising 42% to ₹3,733 crore. Standalone revenue from operations increased 21% to ₹21,192 crore. The standalone EBITDA margin expanded to 26.27% from 23.82% in Q1FY26.
What the Numbers Show
The divergence between revenue growth and profit expansion highlights improved cost management or product mix optimization. While consolidated revenue increased by approximately 21%, net profit surged by over 72%, indicating that the company retained a larger share of each rupee earned. The nearly 5 percentage point jump in EBITDA margin suggests that operating expenses did not scale proportionally with sales, allowing for greater earnings conversion during the period. Additionally, finance costs declined 36% to ₹119 crore, further supporting bottom-line growth.
Historical Stock Returns for IPCA Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.66% | +1.76% | -1.50% | +21.94% | +30.46% | +50.47% |
Can the 107% surge in institutional export sales be sustained in Q2FY27, or was it driven by one-off large orders?
How will the recent 36% decline in finance costs impact IPCA's long-term debt servicing capacity and future capital allocation strategies?
What specific product mix optimizations contributed to the 449 bps expansion in EBITDA margins, and are these gains replicable across other quarters?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
